Market News
Stay updated with the latest market trends, earnings, and economic indicators.
True North cashes out $2 billion for investors as PE firms step up exits
This comes on the back of exits for True North from portfolio firms like FedFina, Niva Bupa, Biocon Biologics, Infinity Fincorp Solutions, Zydus Wellness and Home First Finance.
Five Stocks To Buy: Biocon, IndusInd Bank, Angel One And More | July 6, 2026
Five stocks to buy on July 6.
Analysts back buy-on-dips strategy as Nifty targets 24,450–24,800
Indian stock market analysts are optimistic, anticipating the Nifty to continue its upward trend. They suggest buying on dips around the 24,000-24,150 mark, with potential upside targets reaching 24,800. Several stocks, including Container Corporation of India, IndusInd Bank, Biocon, HDFC Asset Management Company, Shriram Finance, and Piramal Pharma, are highlighted as strong buy recommendations with specific price targets and stop-losses.
Stocks to Watch today: HDFC Bank, Biocon, SJVN, Container Corp, Yes Bank
Stocks to Watch today, June 30, 2026: Tech Mahindra, Axis Bank, Godrej Properties, RITES, SIS, Jagsonpal Pharma, and Sterling and Wilson Renewable Energy are top stocks to remain in focus
Dividend Stocks To Watch Next Week: Bajaj Finance, M&M, Tech Mahindra, Welspun Corp, Biocon — Check Amount, Record Date
Dividend Stocks to Watch
Corporate Actions This Week: Bajaj Finance, Biocon, Bharat Forge, M&M To Trade Ex-Dividend | Full List
Corporate actions include dividend payouts and share buyback.
Buy or sell: Gift Nifty signals gap-up opening, Vaishali Parekh recommends three stocks to buy today — 23 June 2026
Buy or sell stocks, 23 June 2026: Vaishali Parekh recommends three stocks to buy today — Hindustan Zinc, Biocon, and Adani Green Energy
Laurus Labs, Biocon, Ather Energy, Lenskart among probable MSCI India Standard Index inclusion candidates, says JM Financial
JM Financial anticipates significant shifts in the MSCI India Standard Index. Laurus Labs and Biocon are flagged as high-probability additions from the Small Cap Index, while Ather Energy and SAIL are medium-probability candidates. SBI Card faces a high probability of exclusion. These potential changes could lead to substantial passive fund inflows into India, estimated around $3.2 billion, impacting institutional investors.
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for Biocon
Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalizing on growing demand as major pharmaceutical companies shift focus to newer weight-loss drugs. Currently the third-largest global insulin provider, Biocon is significantly expanding production. This strategic move addresses a critical gap in the market, particularly in emerging economies.
Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift
Nandan Kulkarni, Director–India Healthcare & Senior Research Analyst at Bernstein, sees strong opportunities in CDMOs, specialty therapies, biosimilars and licensing deals. While favouring Zydus, Lupin and Sun Pharma, he remains cautious on Biocon and Mankind Pharma, and argues that India's shift from generics to innovation could drive the next phase of growth for the pharma industry.
Gland Pharma to Biocon: Pharma stocks rally up to 27% in a month: Can they shield portfolio from US-Iran war-led risks?
The Nifty Pharma index has surged nearly 11% over the past month, significantly outperforming the Nifty 50, which declined 3.6% during the same period. On a year-to-date (YTD) basis, the Nifty Pharma index has gained 9.4%, while the benchmark Nifty 50 has fallen by an equal margin.
Biocon Ltd spurts 2.76%, rises for fifth straight session
Biocon Ltd is quoting at Rs 430.55, up 2.76% on the day as on 12:44 IST on the NSE. The stock is up 26.86% in last one year as compared to a 5.01% slide in NIFTY and a 13.99% slide in the Nifty Pharma.